164 related articles for article (PubMed ID: 34629258)
1. Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study.
Morieri ML; Targher G; Lapolla A; D'Ambrosio M; Tadiotto F; Rigato M; Frison V; Paccagnella A; Simioni N; Avogaro A; Fadini GP
Nutr Metab Cardiovasc Dis; 2021 Nov; 31(12):3474-3483. PubMed ID: 34629258
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care.
Morieri ML; Vitturi N; Avogaro A; Targher G; Fadini GP;
J Endocrinol Invest; 2021 Sep; 44(9):1879-1889. PubMed ID: 33432553
[TBL] [Abstract][Full Text] [Related]
3. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.
Colosimo S; Ravaioli F; Petroni ML; Brodosi L; Marchignoli F; Barbanti FA; Sasdelli AS; Marchesini G; Pironi L
Liver Int; 2021 Apr; 41(4):731-742. PubMed ID: 33497019
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.
Makri E; Kita M; Goulas A; Papaioannidou P; Efstathiadou ZA; Adamidou F; Polyzos SA
Diabetes Metab Syndr; 2020; 14(6):1913-1919. PubMed ID: 33011499
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.
Yabut JM; Drucker DJ
Endocr Rev; 2023 Jan; 44(1):14-32. PubMed ID: 35907261
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
8. Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
Carretero-Gómez J; Carrasco-Sánchez FJ; Fernández-Rodríguez JM; Casado-Escribano P; Miramontes-González JP; Seguí-Ripoll JM; Ena J; Arévalo-Lorido JC;
Rev Clin Esp (Barc); 2023 Mar; 223(3):134-143. PubMed ID: 36549643
[TBL] [Abstract][Full Text] [Related]
9. Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study.
Corbin KD; Pittas AG; Desouza C; Grdinovac KK; Herzig KH; Kashyap SR; Kim SH; Nelson J; Rasouli N; Vickery EM; Knowler WC; Pratley RE
J Diabetes Complications; 2023 Jun; 37(6):108475. PubMed ID: 37104979
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes.
Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
Eur J Prev Cardiol; 2021 Mar; 28(1):22-29. PubMed ID: 33624059
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
Brunton S
Int J Clin Pract; 2014 May; 68(5):557-67. PubMed ID: 24499291
[TBL] [Abstract][Full Text] [Related]
12. Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years.
Lee HW; Lee JS; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Diabetes Complications; 2021 Jan; 35(1):107747. PubMed ID: 33616043
[TBL] [Abstract][Full Text] [Related]
13. Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus.
Csermely A; Mantovani A; Morieri ML; Palmisano L; Masulli M; Cossu E; Baroni MG; Bonomo K; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Aldigeri R; Cas AD; de Kreutzenberg SV; Targher G
Diabetes Metab; 2023 Nov; 49(6):101477. PubMed ID: 37708990
[TBL] [Abstract][Full Text] [Related]
14. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Harrison SA; Frias JP; Lucas KJ; Reiss G; Neff G; Bollepalli S; Su Y; Chan D; Tillman EJ; Moulton A; de Temple B; Zari A; Shringarpure R; Rolph T; Cheng A; Yale K
Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38447814
[TBL] [Abstract][Full Text] [Related]
16. Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Ordóñez-Vázquez AL; Beltrán-Gall SM; Pal SC; Méndez-Sánchez N
Med Sci Monit; 2022 Sep; 28():e938365. PubMed ID: 36093924
[TBL] [Abstract][Full Text] [Related]
17. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Campos C; Unger J
Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis.
Jianping W; Xuelian Z; Anjiang W; Haiying X
J Clin Gastroenterol; 2021 Aug; 55(7):586-593. PubMed ID: 34039937
[TBL] [Abstract][Full Text] [Related]
19. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.
Weeda ER; Muraoka AK; Brock MD; Cannon JM
Int J Clin Pract; 2021 Sep; 75(9):e14060. PubMed ID: 33527605
[TBL] [Abstract][Full Text] [Related]
20. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
